BioNotebook: Sanofi partner Merrimack reports failure, but shares jump on Actavis deal
This article was originally published in Scrip
Executive Summary
Merrimack Pharmaceuticals said its experimental drug partnered with Sanofi failed in a breast cancer study, adding to a list of clinical disappointments.